31.18
-0.15 (-0.48%)
| Penutupan Terdahulu | 31.33 |
| Buka | 30.48 |
| Jumlah Dagangan | 6,083,263 |
| Purata Dagangan (3B) | 2,659,472 |
| Modal Pasaran | 3,613,573,120 |
| Harga / Buku (P/B) | 7.35 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Jul 2026 |
| EPS Cair (TTM) | -1.54 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.11% |
| Nisbah Semasa (MRQ) | 25.86 |
| Aliran Tunai Operasi (OCF TTM) | -152.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -102.10 M |
| Pulangan Atas Aset (ROA TTM) | -14.99% |
| Pulangan Atas Ekuiti (ROE TTM) | -19.99% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Viking Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -0.25 |
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.15% |
| % Dimiliki oleh Institusi | 70.06% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 21 Apr 2026 | CNBC | Amazon launches GLP-1 weight loss program, promising 'fast, convenient' access |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |